Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875307 | 0.81 | CA2 (0.35) | CA2CA12CA1CA9CHKA | |
| SCHEMBL15355468 | 0.80 | — | — | |
| SCHEMBL2721518 | 0.80 | MLYCD (0.33) | — | |
| SCHEMBL27473154 | 0.79 | SIGMAR1 (0.35) | CA2CA12CA1CA9CHKA | |
| SCHEMBL980149 | 0.78 | MLYCD (0.32) | — | |
| Hydrochloric Acid SCHEMBL7098403 | 0.78 | HPGD (0.37) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL27722005 | 0.78 | HPGD (0.37) | CA2CA12CA1CA9CHKA | |
| SCHEMBL22442213 | 0.77 | KDM4E (0.33) | — | |
| SCHEMBL27480810 | 0.75 | — | — | |
| SCHEMBL14812645 | 0.75 | SMN1; SMN2 (0.40) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101935311-B | Piperazinium trifluoroacetate compound and carbon dioxide absorbent using the same | HYUNDAI MOTOR CO LTD | 2015-06-10 | — | — | CN | claimed |
| US-8287627-B2 | Piperazinium trifluoroacetate compound and carbon dioxide absorbent using the same | HYUNDAI MOTOR COMPANY (KR) | 2012-10-16 | — | — | US | claimed |
| CN-101935311-A | Piperazinium trifluoroacetate compound and carbon dioxide absorbent using the same | HYUNDAI MOTOR CO LTD | 2011-01-05 | — | — | CN | claimed |
| US-20100326277-A1 | PIPERAZINIUM TRIFLUOROACETATE COMPOUND AND CARBON DIOXIDE ABSORBENT USING THE SAME | HYUNDAI MOTOR COMPANY (KR) | 2010-12-30 | — | — | US | claimed |
| CN-100482651-C | Diaminothiazoles | HOFFMANN LA ROCHE (CH) | 2009-04-29 | — | — | CN | claimed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2025120168-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CRYPTOSPORIDIUM INFECTIONS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) | 2025-06-12 | — | — | WO | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| CN-110088098-A | Quinazolinones PARP-1 inhibitor and preparation method thereof, pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2019-08-02 | — | — | CN | disclosed |
| CN-108707139-A | Amino-metadiazine compound and its preparation method and application | 北京浦润奥生物科技有限责任公司 | 2018-10-26 | — | — | CN | disclosed |
| CN-104736535-B | Heterocyclic modulators of HIF activity for treatment of disease | 德州大学系统董事会 | 2017-12-19 | — | — | CN | disclosed |
| CN-1278793-A | Sulfonyl derivatives | DAIICHI SEIYAKU CO (JP) | 2001-01-03 | — | — | CN | disclosed |
| CN-1230196-A | Modified aminoacids, pharmaceuticals containing these compounds and method for their prodn. | THOMAE GMBH DR K (DE) | 1999-09-29 | — | — | CN | disclosed |
| CN-1044236-C | Oxazolidinone antimicrobials containing substituted diazine moieties | PHARMACIA UPJOHN CO (US) | 1999-07-21 | — | — | CN | disclosed |
| CN-1154699-A | (Azetidin-1-ylalkyl) lactams as tachykinin antagonists | PFIZER LTD (IE) | 1997-07-16 | — | — | CN | disclosed |
| CN-1030767-C | 1-methylcarbapenem derivatives, their preparation and their use as antibiotics | SANKYO CO (JP) | 1996-01-24 | — | — | CN | disclosed |
| CN-1079964-A | The (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides antiseptic-germicide that contains the substituted diazine moieties base | UPJOHN CO (US) | 1993-12-29 | — | — | CN | disclosed |
| CN-1070399-A | The amide derivatives oxytocin antagonist that piperizinylcamphorsuoxytocin replaces | MERCK & CO INC (US) | 1993-03-31 | — | — | CN | disclosed |
| CN-1069494-A | 1-methylcarbapenem derivatives, its preparation and antibiotic purposes thereof | SANKYO CO (JP) | 1993-03-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100326277-A1 | PIPERAZINIUM TRIFLUOROACETATE COMPOUND AND CARBON DIOXIDE ABSORBENT USING THE SAME | SLC16A7, SLC16A1, SLC16A3 | CA2 10/4885CA12 142/4885CA1 82/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | CA2 661/4885CA12 2420/4885CA1 2103/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | CA2 4378/4885CA12 4587/4885CA1 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.